DTaP5-IPV-Hib-HepB1 (Six in One) vaccine filed at FDA- Merck Inc. + Sanofi Pasteur
Merck and Sanofi Pasteur, the vaccines division of Sanofi have announced that the Biologics License Application (BLA) filed for the companies� investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1, has been accepted for review by the FDA. If approved, it would be the first pediatric combination vaccine in the United States designed to help protect against six important diseases � diphtheria, tetanus, pertussis (whooping cough), polio (poliovirus types 1, 2, and 3), invasive disease caused by Haemophilus influenzae type b (Hib), and hepatitis B.
The Six in One vaccine was approved in the EU in 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins